-+ 0.00%
-+ 0.00%
-+ 0.00%

Annexin Enrolls Last Patient in Mid-stage Trial of Eye Disease Drug Candidate

MT Newswires·10/22/2026 05:58:22
Listen to the news
05:58 AM EDT, 10/22/2026 (MT Newswires) -- Annexin Pharmaceuticals (ANNX.ST) has completed patient enrollment in its phase 2a Nexus study of the drug candidate vanexin, which includes patients with retinal vein occlusion and diabetic retinopathy. The Swedish biotech company said Thursday that the 12th and final patient enrolled in the study is receiving vanexin after an initial anti-vascular endothelial growth factor injection. Annexin plans to implement the treatment strategy into a phase 2b study. The company expects to report the topline data by the end of the first quarter of 2027.